Mild Cognitive Impairment (MCI) represents a critical therapeutic window between normal aging and [Alzheimer's Disease](/diseases/alzheimers-disease) dementia. Defined as objective cognitive impairment beyond age-expected norms with preserved functional abilities[@Petersen2018], MCI affects approximately 15-20% of individuals over 65 and serves as the optimal intervention point for disease-modifying therapies. The 2023-2024 approvals of [lecanemab](/entities/lecanemab) and [donanemab](/entities/donanemab) have validated amyloid-targeting in early-stage disease, fundamentally reshaping the MCI investment landscape[@van2023][@Sims2023].
Last updated: 2026-03-29 12:15 PT
Clinical Trial Pipeline
MCI represents one of the most active therapeutic areas in neurodegeneration:
| Phase | AD/MCI Trials | Notes | |-------|---------------|-------| | Phase 1 | 480+ | Including prevention cohorts | | Phase 2 | 630+ | Largest concentration of programs | | Phase 3 | 320+ | Amyloid antibodies, symptomatic agents | | Total Active | 1,200+ | Includes MCI-specific and AD with MCI cohorts |
...
Investment Landscape: Mild Cognitive Impairment
Overview
Mild Cognitive Impairment (MCI) represents a critical therapeutic window between normal aging and [Alzheimer's Disease](/diseases/alzheimers-disease) dementia. Defined as objective cognitive impairment beyond age-expected norms with preserved functional abilities[@Petersen2018], MCI affects approximately 15-20% of individuals over 65 and serves as the optimal intervention point for disease-modifying therapies. The 2023-2024 approvals of [lecanemab](/entities/lecanemab) and [donanemab](/entities/donanemab) have validated amyloid-targeting in early-stage disease, fundamentally reshaping the MCI investment landscape[@van2023][@Sims2023].
Last updated: 2026-03-29 12:15 PT
Clinical Trial Pipeline
MCI represents one of the most active therapeutic areas in neurodegeneration:
| Phase | AD/MCI Trials | Notes | |-------|---------------|-------| | Phase 1 | 480+ | Including prevention cohorts | | Phase 2 | 630+ | Largest concentration of programs | | Phase 3 | 320+ | Amyloid antibodies, symptomatic agents | | Total Active | 1,200+ | Includes MCI-specific and AD with MCI cohorts |
Key active trials:
[NCT06072963](https://clinicaltrials.gov/study/NCT06072963): Semaglutide in MCI/combat PTSD — GLP-1 in cognitive protection
[NCT07392723](https://clinicaltrials.gov/study/NCT07392723): ALA in APOE4+ MCI — antioxidant approach for genetic risk
[NCT04123314](https://clinicaltrials.gov/study/NCT04123314): Psilocybin in MCI/AD — psychedelic-assisted therapy for neuroplasticity
A4 Trial: Anti-Amyloid treatment in asymptomatic MCI (preclinical AD)
DIAN-TU: Disease-modifying therapies in autosomal dominant AD with MCI endpoints
Investment Context
MCI represents the most commercially attractive intervention point in neurodegeneration:
Key Investment Themes
Disease modification in early stages: Lecanemab and donanemab trials demonstrated greatest benefit in MCI/early AD populations[@cummings2024]
[Petersen RC, et al, Mild Cognitive Impairment: clinical characterization and outcome (2018)](https://pubmed.ncbi.nlm.nih.gov/30648636/)
[Cummings J, et al, Alzheimer's Disease Drug Development Pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38427984/)
[van Dyck CH, et al, Lecanemab in Early Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36449415/)
[Sims JR, et al, Donanemab in Early Symptomatic Alzheimer Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37573066/)
[Hansson O, Biomarkers for Alzheimer's Disease in Clinical Practice (2024)](https://pubmed.ncbi.nlm.nih.gov/38554251/)
[Sabbagh MN, et al, MCI to Alzheimer's disease: current diagnostic approaches and emerging therapies (2020)](https://pubmed.ncbi.nlm.nih.gov/32530720/)